Why the BARD1 (ASX:BD1) share price shot up 10% today

The BARD1 Life Sciences Limited (ASX: BD1) share price rocketed 9.71% on opening today after the company signed an agreement with the University of Liverpool.

The agreement is the first step towards licensing BARD1’s blood test, which the company hopes will diagnose novel type 3c diabetes. So far, the test has shown promise in preliminary testing. The ability to diagnose type 3c diabetes and other technology BARD1 currently has in the works may help diagnose pancreatic cancer.

After peaking in early trade at $3.71, the BARD1 share price has since lost ground and is now swapping hands at $3.45, up 2.37% at the time of writing. 

Let’s look closer at today’s announcement from the medical diagnostic company.

New options…